KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vir Biotechnology (VIR) Equity Income (2021 - 2025)

Historic Equity Income for Vir Biotechnology (VIR) over the last 5 years, with Q3 2025 value amounting to $1.3 million.

  • Vir Biotechnology's Equity Income rose 1814.16% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 15987.68%. This contributed to the annual value of -$5.5 million for FY2024, which is 7475.8% up from last year.
  • Per Vir Biotechnology's latest filing, its Equity Income stood at $1.3 million for Q3 2025, which was up 1814.16% from -$3.4 million recorded in Q2 2025.
  • Vir Biotechnology's Equity Income's 5-year high stood at $164.1 million during Q3 2021, with a 5-year trough of -$95.0 million in Q1 2022.
  • In the last 5 years, Vir Biotechnology's Equity Income had a median value of -$2.7 million in 2023 and averaged $226470.6.
  • Data for Vir Biotechnology's Equity Income shows a peak YoY increase of 20819.95% (in 2025) and a maximum YoY decrease of 89254.08% (in 2025) over the last 5 years.
  • Vir Biotechnology's Equity Income (Quarter) stood at -$26.0 million in 2021, then surged by 134.12% to $8.9 million in 2022, then plummeted by 111.26% to -$1.0 million in 2023, then dropped by 12.8% to -$1.1 million in 2024, then soared by 218.35% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$3.4 million for Q2 2025, and $6.4 million during Q1 2025.